Physician profile
Michael Zimmerer
NPI 1760468268
$2,199.74
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $115 · 2021: $459 · 2022: $677 · 2023: $14.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $466.33 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $277.95 | 2019-2022 | |
| Amgen INC. | $223.46 | 2019-2022 | |
| Allergan, INC. | $209.54 | 2019 | |
| Amarin Pharma, INC. | $182.66 | 2019-2021 | |
| Abbott Laboratories | $137.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $68.69 | 2019-2022 | |
| Pfizer INC. | $41.49 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $40.31 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.72 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $31.56 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.79 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $30.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2022 | |
| Novo Nordisk INC | $27.41 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $26.41 | 2019-2022 | |
| Lilly USA, LLC | $26.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.79 | 2021-2022 | |
| Vivus LLC | $25.74 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.86 | 2019 | |
| Radius Health, INC. | $14.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.95 | 2022 | |
| Currax Pharmaceuticals LLC | $11.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zimmerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.